|4Feb 17, 4:05 PM ET

1315 Capital II, L.P. 4

4 · INTERPACE BIOSCIENCES, INC. · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Interpace (IDXG) 10% Owner Converts Preferred into 9.4M Shares

What Happened
1315 Capital II, L.P. (a reported 10% owner) converted 19,000 shares of Interpace Biosciences' Series C Convertible Preferred Stock into 9,405,941 shares of common stock on January 20, 2026. The conversion used an effective conversion price of $2.02 per common share, producing common shares with an implied value of $19,000,001. The filing shows the preferred shares were disposed (converted) at $0.00 and the common shares were acquired via conversion (transaction code C).

Key Details

  • Transaction date: January 20, 2026 (reported on Form 4 filed February 17, 2026 — filed late).
  • Conversion math: Each Series C had an initial stated value of $1,000 and converted at an initial conversion price of $2.02 per share (see footnote).
  • Shares received: 9,405,941 common shares; Series C preferred shares disposed: 19,000.
  • Total implied value: $19,000,001 (9,405,941 shares × $2.02).
  • Recordholder/relationships: Securities held of record by 1315 Capital II, L.P.; 1315 Capital GP II, L.P. and 1315 Capital Ultimate Holdings, LLC are general partners and may be deemed to have voting/investment power but disclaim beneficial ownership except to the extent of pecuniary interest (footnotes F3–F4).
  • Other notable footnotes: Series C had no expiration date (F5); conversion formula described in footnote F2.
  • Shares owned after transaction: Not specified in the provided filing.

Context

  • This was a conversion of convertible preferred into common stock (a derivative conversion), not an open-market purchase or sale. Conversions increase the company’s outstanding common shares (dilutive in effect) but do not indicate a market-sale by the reporting holder.
  • The filer is a 10% institutional holder, not an insider officer or director trading on personal liquidity; institutional conversions often reflect financing or capital structure terms rather than short-term sentiment.
  • The Form 4 was filed late (filed Feb 17 for a Jan 20 transaction); late filings reduce transparency and can carry regulatory attention but do not necessarily imply wrongdoing.

Insider Transaction Report

Form 4
Period: 2026-01-20
Transactions
  • Conversion

    Common Stock

    [F1][F2][F3][F4]
    2026-01-20$2.02/sh+9,405,941$19,000,0019,405,941 total
  • Conversion

    Series C Convertible Preferred Stock

    [F2][F1][F5][F3][F4]
    2026-01-2019,0000 total
    Exercise: $2.02From: 2024-10-11Common Stock (9,405,941 underlying)
Footnotes (5)
  • [F1]On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").
  • [F2]The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.
  • [F3]These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.
  • [F4]Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  • [F5]The Series C Convertible Preferred Stock had no expiration date.
Signature
1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva|2026-02-17

Documents

1 file
  • 4
    ownership.xmlPrimary

    4